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Abstract
Background: People with chronic kidney disease (CKD) have high levels of co-morbidity and polypharmacy placing
them at increased risk of prescribing-related harm. Tools for assessing prescribing safety in the general population
using prescribing safety indicators (PSIs) have been established. However, people with CKD pose different
prescribing challenges to people without kidney disease. Therefore, PSIs designed for use in the general population
may not include all PSIs relevant to a CKD population.
The aim of this study was to systematically collate a library of PSIs relevant to people with CKD.
Methods: A systematic literature search identified papers reporting PSIs. CKD-specific PSIs were extracted and
categorised by Anatomical Therapeutic Chemical (ATC) classification codes. Duplicate PSIs were removed to create
a final list of CKD-specific PSIs.
Results: Nine thousand, eight hundred fifty-two papers were identified by the systematic literature search, of which
511 proceeded to full text screening and 196 papers were identified as reporting PSIs. Following categorisation by
ATC code and duplicate removal, 841 unique PSIs formed the final set of CKD-specific PSIs. The five ATC drug
classes containing the largest proportion of CKD-specific PSIs were: Cardiovascular system (26%); Nervous system
(13.4%); Blood and blood forming organs (12.4%); Alimentary and metabolism (12%); and Anti-infectives for
systemic use (11.3%).
Conclusion: CKD-specific PSIs could be used alone or alongside general PSIs to assess the safety and quality of
prescribing within a CKD population.
Keywords: Chronic kidney disease, CKD, Primary care population, Outpatient setting, Prescribing safety, Potentially
inappropriate prescribing, Prescribing safety indicators
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Background
People with chronic kidney disease (CKD) stand to
benefit from careful prescribing of medications to pre-
vent disease progression, manage comorbidities and re-
lieve symptoms [1]. Meanwhile they are at increased risk
of prescribing-related harm as a result of incorrect dos-
ing considering altered drug clearance or direct nephro-
toxicity. Adverse drug events are common in the CKD
population and interventions to optimise prescribing
have shown promise [2]. However, current approaches
for optimising prescribing in this patient group are lim-
ited [1–3].
Prescribing safety indicators (PSIs) distinguish pre-
scribing events that put a patient at risk of harm [4]. PSI
libraries for different patient populations have been col-
lated through expert consensus, review of clinical guide-
lines, and systematic searching of published literature.
One systematic approach to the identification of PSIs
conducted by Spencer et al. in 2012 collated 56 indica-
tors relevant to the general primary care population [4].
Whilst such a library is applicable to a CKD population,
prescribing events of unique importance to people with
kidney disease may be inadequately represented when
considering pharmacotherapy for this group in isolation.
The aim of this study was to use a systematic search of
the published literature to produce a library of PSIs spe-
cific to outpatient prescribing for people with CKD. This
library could be used alone or alongside general PSIs to
assess the safety and quality of prescribing within a CKD
population.
Methods
A protocol was written to collate PSIs with specific rele-
vance to people with CKD from the published literature
(PROSPERO CRD42018109113). A systematic literature
search to identify papers reporting PSIs was followed by
extraction of CKD-specific PSIs. Pre-defined criteria
classified PSIs as CKD-specific if they were of exclusive
relevance to adults (age ≥ 18) with CKD and referring to
medications prescribed within the outpatient setting.
Systematic literature search
A sensitive search strategy was designed to capture all
potentially relevant papers reporting PSIs. To capture
PSIs from the general primary care population the
search strategy used by Spencer et al. was updated to in-
clude literature published from 2012 until 2018 [4].
Search terms related to three stems – clinical setting,
prescribing and tool type. To reflect hospital-based de-
livery of advanced CKD care, a supplementary CKD-
specific search was developed with revision of the clin-
ical setting stem terms, and the addition of a stem for
kidney-disease. CKD terms were chosen to capture all
stages of CKD, including end-stage. This supplementary
search was run from inception (1946 to 2018). Both
searches were conducted in October 2018 using Med-
line, Embase, Pubmed, Web of Science and CINAHL. A
full list of terms used in each search is available in Add-
itional file 1: Appendix 1 (Table 3, 4).
Results from the two searches were combined and du-
plicate results were removed. Titles and abstracts were
independently screened by two of the authors (FS, GK).
An inclusive approach was used, excluding only those
records from non-human or paediatric work (age < 18
years) or those referring solely to prescribing in an in-
patient setting. There was no selection for CKD-specific
PSIs made at this stage. If a record was recommended
for inclusion by one of the reviewers it progressed to full
text screening.
PSI extraction and selection of CKD-specific PSIs
Full-text screening was conducted by FS. Publications
reporting one or more PSI in the main text, abstract or
tables of the publication were included. The details of all
PSIs from the literature search were entered into a data
extraction form by FS. The elements extracted included
details relating to the publication itself – title; authors;
journal; date of publication; study design; setting; target
population; methodology and method of indicator devel-
opment – in addition to exact replication of each PSI
from the original publication.
A two-stage process followed to identify CKD-specific
PSIs. Firstly, an automated filter was developed to short-
list possible CKD-specific PSIs. The automated CKD-
specific filter terms (Additional file 1: Appendix 2:
Table 5) were adapted and iteratively developed from
the original search terms, through repeated comparisons
between the automated process and manual review of a
random sample of PSIs from the master list (BH). The
final filter terms were selected once no manually in-
cluded PSI was excluded by the automated process in a
random sample of 100 PSIs. The output from this auto-
mated process was then divided between three authors
(FS, BH, SH) who manually selected CKD-specific PSIs.
Classification and categorisation of PSIs
Each CKD-specific PSI was labelled with the Anatomical
Therapeutic Chemical (ATC) codes of each medication
listed in the prescribing statement [5]. Duplicate PSIs
and those not meeting pre-specified criteria were manu-
ally removed. In order to be classified as duplicates, two
PSIs had to replicate the following information: identical
drug, identical level of kidney function and identical pre-
scribing rule. If a PSI was found to contain multiple
rules, with other PSIs duplicating individual rules, then
only the PSI containing the most information was main-
tained. Following duplicate removal, it was possible to
identify the proportion of PSIs defined by their ATC
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Fig. 1 Systematic review results and PSI extraction
Table 1 PSI examples
CKD-specific PSIs General PSIs [not included in CKD-specific PSI library]
1. Metformin - not recommended in patients with eGFR < 45 and
contraindicated in patients with eGFR < 30 [ATC code: A10BA]
1. Prescribing a traditional oral NSAID or low-dose aspirin in patients with
a history of peptic ulceration without co-prescription of gastro- protection
2. Rivaroxaban - Caution in case of CrCl 15–30 ml/min - dose reduction
to 15mg/ day [ATC code: B01AF]
2. Significant drug-disease interactions in patients aged 65 and over: Con-
gestive heart failure (systolic dysfunction) - first generation calcium chan-
nel blockers eg verapamil, diltiazem
3. Lithium - measure calcium and serum lithium levels at start of
treatment; 3 monthly renal function; 6 monthly thyroid function, calcium,
weight and serum lithium levels [ATC code: N05AN]
3. Management - Associated adverse therapeutic outcome in patients
aged over 65: Use of theophylline without drug level monitoring at least
every 6 months - theophylline toxicity
4. Drugs requiring dosage adjustment in patients with impaired kidney
function and aged 65 and over: Opioids [ATC code: N02A]
4. Prescribing indicators for patients aged >65a: Patient with OA pain
interfering with daily activities has been trialled on paracetamol
(acetaminophen) 2–4 g/day
5. Medicines that may accumulate and require renal function
monitoring: ARBs [ATC code: C09CA]
5. Methotrexate prescriptions should state ‘weekly’
GFR glomerular filtration rate, CrCl creatinine clearance, NSAID non-steroidal anti-inflammatory drug
aie what patients SHOULD be taking
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classification and subsequently further divide PSIs in re-
lation to the most frequent medication classes.
Results
In total 9852 papers were identified by the two searches
(CKD search 5223; general population search 4629). Fol-
lowing title and abstract screening 511 papers proceeded
to full text screening (CKD search = 425; general popula-
tion search = 86). Of the 511 articles, 315 did not contain
any PSIs. PSI extraction was performed from the
remaining 196 articles, with a total of 3464 PSIs identi-
fied. [Fig. 1] The full list of 3464 PSIs was filtered to
identify 1775 of potential relevance to people with CKD.
These PSIs were reviewed by three of the authors (FS,
SH, BH) with 1231 confirmed as CKD-specific.
The CKD-specific PSIs were classified by ATC code.
Three hundred seventy-one duplicates were identified
and excluded. A further 19 were deemed not to fit the
pre-specified criteria after discussion between reviewing
authors (6 related to inpatient prescribing and 13 were
deemed not to be CKD-specific). The remaining 841
unique PSIs became the final set of CKD-specific PSIs.
Examples of PSIs are demonstrated in Table 1 (full list is
in Additional file 2: Appendix 3).
CKD-specific PSIs
PSIs were found to take multiple different forms, includ-
ing those that referred to single drugs (Table 1: Items 1–
3), to drug classes (Item 4), and to lists of agents with
particular pharmacokinetic or dynamic properties (Item
5). Some PSIs specified thresholds or ranges of kidney
function (Item 1). Others referred to kidney disease non-
specifically (Items 4 & 5). A variety of methods for esti-
mating kidney function were cited, including CrCl and
eGFR/GFR, though no PSI specified a method for eGFR/
GFR calculation. Table 2 shows the final number of PSIs
per ATC drug classification. The five ATC drug classes
containing the largest proportion of CKD-specific PSIs
were: Cardiovascular system (26%); Nervous system
(13.4%); Blood and blood forming organs (12.4%); Ali-
mentary and metabolism (12%); and Anti-infectives for
systemic use (11.3%). Additionally, Table 2 shows the
most frequent medication classes referred to in each
ATC category.
Patient and public involvement
Patients or the public were not involved in the design, or
conduct, or reporting, or dissemination plans of our
research.
Discussion
Using a systematic search strategy and manual extrac-
tion, a library of 841 CKD-specific PSIs were identified.
Indicators relating to all but one ATC drug class
(dermatologicals) were found, with the majority consid-
ering cardiovascular, nervous and haematological pre-
scribing. Drugs acting on the renin-angiotensin system,
non-vitamin K oral anticoagulants, anti-diabetic medica-
tions, lipid-modifying agents, and antidepressants were
particularly frequent. This library of CKD-specific PSIs
is a first step towards generation of prescribing safety as-
sessments and interventions for populations with CKD.
CKD, defined by persistently abnormal glomerular fil-
tration rate (GFR), and/or other evidence of damage or
structural abnormality, has a global prevalence approxi-
mating 13% [6, 7]. The pharmacokinetic and pharmaco-
dynamic effects of CKD and kidney replacement therapy
increase the risk of drug-related harm for the CKD
population, and inappropriate prescriptions are more
frequent as kidney function declines [1, 8]. Direct
nephrotoxicity (e.g. from aminoglycosides and non-
steroidal anti-inflammatory drugs) and idiosyncratic re-
actions (e.g. with metformin) add further complications
[8]. The need for prescribers to consider GFR is recog-
nised in international guidance for the management of
CKD [7]. Nevertheless, reported rates of GFR-
inappropriate prescriptions (according to the Summary
of Product Characteristics - SPCs) range between 9 and
81% for people with CKD [1, 2].
Prescribing for people with CKD is further compli-
cated by comorbid illness. CKD is both a cause and con-
sequence of comorbidity, most notably microvascular,
macrovascular and cardiac disease. Since the prevalence
of CKD increases with age, acquisition of concurrent ill-
ness is frequent. People living with CKD may thus be
recommended medications to manage causal conditions,
coincidental co-morbidity, and complications of low-
renal function – alongside agents which are preventative
against cardiovascular disease and end stage kidney dis-
ease. Unsurprisingly, this can lead to the prescription of
numerous drugs [1, 9]. The prevalence of polypharmacy
– defined as the regular use of five or more medications
per day – was almost 80% in a cohort of over 5000 Ger-
man people with CKD [10]. Indeed, for older people
with advanced CKD, the prevalence of polypharmacy is
even higher (91%) and hyperpolypharmacy – defined as
10 or more medications – is common (43%) [11]. Poly-
pharmacy increases the likelihood of inappropriate pre-
scriptions and is associated with hospitalisation and
death in people with CKD [1, 12].
An additional factor influencing renal prescribing is
that conventional estimates of GFR use serum creatin-
ine, which is affected by muscle mass and protein intake.
Prescribers must be alert that age-related changes in
body composition may result in lower accuracy of eGFR.
KDIGO recommends prescribers use the most accurate
method for GFR estimation when drug dosing [6]. Esti-
mation of GFR using cystatin C is superior to creatinine-
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Table 2 Final set of CKD-specific PSIs by ATC drug class and further subdivision to most frequently featured medication classes in
each ATC category
ATC drug class CKD-specific PSIs
(n, %)
Top 5 medications in the ATC drug class Number of CKD-specific PSIs
(n, % of total 841 PSIs)
Cardiovascular system 219 (26.0) Agents acting on the renin-angiotensin system 81 (9.6)
Diuretics 48 (5.7)
Lipid modifying agents 44 (5.2)
Beta blocking agents 14 (1.7)
Digitalis glycosides 11 (1.3)





Blood and blood forming organs 104 (12.4) Direct factor Xa inhibitors 36 (4.3)
Direct thrombin inhibitors 31 (3.7)
Antithrombotic agents 9 (1.1)
Heparins 7 (0.8)
Other antianaemic preparations 7 (0.8)
Alimentary and metabolism 101 (12.0) Sulfonylureas 19 (2.3)
DPP-4 inhibitors 12 (1.4)
GLP-1 analogues 12 (1.4)
Biguanides 10 (1.2)
SGLT2 inhibitors 7 (0.8)
Anti-infectives for systemic use 95 (11.3) Other antibacterials 16 (1.9)
Nucleoside and nucleotide reverse transcriptase
inhibitors
13 (1.5)
Beta-lactam antibacterials, penicillins 7 (0.8)




81 (9.6) Other anti-neoplastic agents 27 (3.2)
Alkylating agents 16 (1.9)
Anti-metabolites 14 (1.7)
Cytotoxic antibiotics and related substances 9 (1.1)
Plant alkaloids and other natural products 6 (0.7)




Antigout preparations 14 (1.7)
Other centrally acting agents 2 (0.2)
Other drugs affecting bone structure and
mineralisation
2 (0.2)
Antiparasitic products, insecticides and
repellents
15 (1.8) Aminoquinolones 7 (0.8)
Biguanides 6 (0.7)
Agents against leishmaniasis and trypanosomiasis 1 (0.1)
Genito-urinary and sex hormones 14 (1.7) Drugs for urinary frequency/incontinence 8 (1.0)
Drugs for erectile dysfunction 4 (0.5)
Other urologicals 1 (0.1)
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based approaches [13]. Cystatin-C estimation is likely to
be adequate in most settings, with measurement using
exogenous markers or creatinine clearance employed
only where an accurate measure of GFR is required. It is
noteworthy that the collated PSIs variably included
eGFR, GFR and creatinine clearance, with very few
recommending a method of estimation. This is likely to
reflect an historical literature in an advancing field and
identifies a clear area for improvement.
Clinical support systems such as computerised alerts,
manual-review and eGFR-prompts have been used to re-
duce inappropriate prescribing in CKD populations, and
can be effective in both inpatient and outpatient settings
[2]. Nevertheless, these may over-estimate prescribing
errors, especially of drugs for which the benefit/risk ratio
may remain high even in the setting of very low GFR –
for example those acting on the renin-angiotensin axis
[7]. As such, to what degree ‘inappropriate’ prescriptions
for people with CKD reflect calculated benefit/risk deci-
sions versus injudicious prescribing is unclear. Expert re-
view of individual prescriptions are likely to be difficult
and costly to apply to large populations of individuals
with CKD [2]. Meanwhile, simple interventions such as
eGFR prompts appear ineffective and prescribing guid-
ance can be unclear – for example, multiple eGFR calcu-
lations are used in SPCs [2]. Better approaches for
identification of potential drug harm and targeting of in-
terventions may exist. Harmonisation of product charac-
teristics and GFR estimates with prescribing practice
norms may help. Successful approaches to develop
pharmacotherapy screening tools applicable to the eld-
erly have been developed using systematically generated
libraries of PSIs [14, 15]. This approach has advantages
over guideline review alone, which although possible in
defined patient groups (such as people with CKD) may
fail to capture all important prescribing events. The
work reported here aimed to assimilate PSIs specific to
people with CKD as a first-step to the generation of a
prescribing-safety tool for application in this group.
The main strength of this work is the use of an inclu-
sive systematic approach before focussing on CKD-
specific PSIs. This process reduces the risk of missing
CKD-specific PSIs that are reported in the general litera-
ture. The main weakness is an output that requires fur-
ther work before application in research or clinical
settings. Removal of near-duplicate PSIs, selection of
uniform dosing and GFR-estimation criteria for individ-
ual agents, appraisal in light of present evidence and
supplementation with PSIs for prescribing events that
did not appear is needed. Such a process will involve ex-
pert appraisal and formal approaches to consensus de-
velopment beyond the scope of this work. Chronic
kidney disease-specific PSIs relating to a wide range of
agents were found, but the frequency of PSIs relating to
particular agents should not be seen as indicative of
the clinical importance of individual agents, and may
simply reflect the frequency with which these agents
are used, and/or general familiarity with their CKD-
specific risks [1].
This work focused on outpatient prescribing for indi-
viduals with CKD, so some agents well-known to present
risks in kidney disease are not captured (e.g. intravenous
aminoglycosides). Inpatient prescribing differs substan-
tially from ambulatory settings, with acute illness, acute
kidney injury and daily prescription review. A separate
approach for collating and categorising PSIs relevant to
this setting is required. A further limitation in this study
is that a single author completed full text screening of
articles recommended for inclusion thus posing a risk of
PSIs being missed from the literature.
Table 2 Final set of CKD-specific PSIs by ATC drug class and further subdivision to most frequently featured medication classes in
each ATC category (Continued)
ATC drug class CKD-specific PSIs
(n, %)
Top 5 medications in the ATC drug class Number of CKD-specific PSIs
(n, % of total 841 PSIs)
Sex hormones 1 (0.1)
Miscellaneous 14 (1.7) Miscellaneous 14 (1.7)
Respiratory system 6 (0.7) Antihistamines for systemic use 5 (0.6)
Anticholinergics 1 (0.1)
Various 6 (0.7) Drugs for treatment of hyperkalemia and
hyperphosphatemia
5 (0.6)
Other renal system diagnostic
radiopharmaceuticals
1 (0.1)
Systemic hormonal preparations 4 (0.5) Parathyroid hormones and analogues 2 (0.2)
Glucocorticoids 1 (0.1)
Somatostatin and analogues 1 (0.1)
Sensory organs 1 (0.1) Antiglaucoma preparations and miotics 1 (0.1)
Dermatologicals 0 – 0
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Conclusion
This study has collated a library of safety indicators re-
lating to outpatient prescribing for people with CKD – a
unique group with a higher proportion of prescribing
challenges. The library generated could be used alone or
alongside general PSIs to generate approaches for assess-
ment of prescribing safety and quality for individuals
and populations with CKD.
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